Desonide
Generic Name: desonide
Brand Names:
Desonide
Desonide Lotion USP, 0.05% contains desonide, a synthetic nonfluorinated corticosteroid for topical dermatologic use with 0.5 mg of desonide per gram in a formulated base.
Overview
Desonide Lotion USP, 0.05% contains desonide, a synthetic nonfluorinated corticosteroid for topical dermatologic use with 0.5 mg of desonide per gram in a formulated base.
Uses
Desonide lotion is a low to medium potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.
Dosage
Apply to affected areas as a thin film two or three times daily depending on severity and discontinue when control is achieved. If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary.
Side Effects
Total incidence of adverse reactions associated with use was approximately 8% including stinging and burning approximately 3%, irritation, contact dermatitis, condition worsened, peeling of skin, and itching.
Warnings
Contraindicated in those patients with a history of hypersensitivity to any of the components. HPA axis suppression risks with prolonged use.
Pregnancy
Should be given to a pregnant woman only if clearly needed due to potential teratogenic effects shown in animal studies.
Storage
Store between 20 to 25 degrees C (68 to 77 degrees F).
Frequently Asked Questions
What is Desonide used for?▼
Desonide lotion is a low to medium potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.
What are the side effects of Desonide?▼
Total incidence of adverse reactions associated with use was approximately 8% including stinging and burning approximately 3%, irritation, contact dermatitis, condition worsened, peeling of skin, and itching.
Can I take Desonide during pregnancy?▼
Should be given to a pregnant woman only if clearly needed due to potential teratogenic effects shown in animal studies.
What are the important warnings for Desonide?▼
Contraindicated in those patients with a history of hypersensitivity to any of the components. HPA axis suppression risks with prolonged use.
Related Medications
Tavaborole Topical Solution, 5%
tavaborole topical solution, 5%
Oxaborole Antifungal [EPC]
11 DESCRIPTION Tavaborole topical solution, 5% contains tavaborole, 5% (w/w) in a clear, colorless alcohol-based solution for topical use. The active ingredient, tavaborole, is an oxaborole antifungal with the chemical name of 5-fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole. The chemical formula is C 7 H 6 BFO 2 , the molecular weight is 151.93 and the structural formula is: Tavaborole is a white to off-white powder.
Levodopa
levodopa
Aromatic Amino Acid [EPC]
11 DESCRIPTION INBRIJA consists of a dry powder formulation of levodopa for oral inhalation with the INBRIJA inhaler. The inhalation powder is packaged in white hypromellose capsules. Each capsule contains a spray-dried powder of 42 mg levodopa active ingredient with 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and sodium chloride. The active component of INBRIJA is levodopa, an aromatic amino acid.
Pantoprazole Sodium Injection
pantoprazole sodium injection
11 DESCRIPTION The active ingredient in pantoprazole sodium for injection (pantoprazole sodium), a PPI, is a substituted benzimidazole, sodium 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl] sulfinyl]-1 H -benzimidazole, a compound that inhibits gastric acid secretion. Its empirical formula is C 16 H 14 F 2 N 3 NaO 4 S, with a molecular weight of 405.4. The structural formula is: Pantoprazole sodium is a white or almost white powder and is racemic.
Medical Disclaimer
This drug information is for educational purposes only and should not replace professional medical advice. Drug information is sourced from the FDA National Drug Code Directory and Structured Product Labeling. Always consult with a healthcare provider before starting, stopping, or changing any medication.